Learn more about UC TechAlerts – Subscribe to categories and get notified of new UC technologies

Browse Category: Medical > New Chemical Entities, Drug Leads

Categories

[Search within category]

Reversing COVID-19 associated ARDS and cytokine storm with N-acetylglucosamine

The rapid emergence and spread of a novel coronavirus disease (COVID-19) has caused a global pandemic. Excessive inflammation leading to acute respiratory distress syndrome (ARDS) is the primary driver of mortality in severe COVID-19 cases, and is yet to be addressed by current therapeutics. Researchers at UCI and Mt. Sinai Hospital have therefore developed an anti-inflammatory treatment using N-acetylglucosamine to lower the mortality and need for ventilators in critically ill COVID-19 patients.

Co-Administration Therapy to Prevent Neurodegeneration and Enhance Neuroprotection

Neurodegenerative diseases are a broad category of illnesses expected to affect 1 in 4 Americans. As they have a variety of underlying mechanisms and pathologies, there are currently no effective methods to prevent or modify disease progression. UCI researchers have developed a potential treatment utilizing a novel combination of two compounds for the abatement of brain inflammation and degeneration.

Novel Prodrug For Anti-Cancer Therapeutic Applications

Inventors at UCI have developed a modified nutrient transporter inhibitor for use as a cancer therapeutic with minimal side effects.

Novel Mixtures For Synergistic Activation Of M-Channels

Epilepsy is a seizure causing neurological disorder that affects over 50 million people, and it is estimated that half are ineffectively treated with current therapeutic options. Researchers at UCI have isolated components of a plant extract used to treat epilepsy in Africa and discovered that, when combined with an existing epilepsy medication, the mixture greatly decreases epileptic episodes and significantly increases survival rates in rodent models of epilepsy.

Metal‐Binding Pharmacophore Library Yields the Discovery of a Glyoxalase 1 Inhibitor for Potential Treatment of Depression and Related Psychiatric Illnesses.

Anxiety and depression are the two most common psychiatric disorders in the U.S. and affect approximately one-in-five adults at some point in their lifetime. Depression is the leading cause of worldwide disability; anxiety disorders are highly comorbid with depression. Presently, there are several drugs approved by the U.S. Food and Drug Administration for the treatment of both anxiety and depression; however, these drugs have several important limitations. Antidepressant drugs are not effective in all patients, take weeks to produce therapeutic effects, and produce side effects that limit their use. Anxiolytic drugs produce sedating side effects and have significant abuse liability. Therefore, there is an urgent need for better therapeutic agents. Recent studies using both genetic and pharmacological techniques have implicated GLO1 in numerous behaviors, including several that are relevant to depression and anxiety.

Fragment-Based Stabilization Of 14-3-3/Client Protein-Protein Interactions

UCSF and Technical University of Eindhoven investigators have identified molecular fragments that stabilize 14-3-3/phospho-peptide and 14-3-3/phospho-protein interactions.  Further structure-guided and empirical medicinal chemistry will lead to a drug lead for the most advanced target (estrogen receptor).   

Hv1 Modulators and Uses

Researchers at UCI have engineered a class of Hv1 polypeptide modulators that selectively modulate Hv1 voltage gated channels while leaving other voltage gated channels unaffected. With no Hv1 modulators currently on the market, this class of Hv1 polypeptide modulators could provide solutions in birth control, autoimmune therapies, and tumor reduction.

Nell-1 As An Anti-Osteoinflammatory, Disease-Modifying Anti-Arthritis Agent

UCLA researchers in the Department of Plastic Surgery and the School of Dentistry have developed a novel anti-osteoinflammatory agent for the prevention and suppression of arthritis disease progression.

Exercise In A Pill: Compounds That Reproduce The Effects Of Exercise On Muscle Metabolism And Growth

UCLA researchers in the Department of Neurology have identified and synthesized small molecule analogs that activate skeletal muscle growth, mediated by calcium calmodulin kinase II signaling.

A New Approach To Treat/Manage Inflammatory Bowel Disease

Researchers at UCI have developed a safe, inexpensive drug for the treatment of inflammatory bowel diseases.

Drug Repurposing To Explore Novel Treatment For Cushing Disease

UCLA researchers in the Department of Medicine and the Department of Molecular and Medicinal Pharmacology have identified several small molecule reagents to treat Cushing disease.

Treatment Of Lysosomal Storage Disorders

UCLA researchers in the Departments of Neurology have developed a novel treatment for Lysosomal-storage diseases (LSDs) with neurological impairment.

New Drug Class for Treating Multiple Sclerosis

UCLA researchers from the Department of Molecular & Medical Pharmacology have developed a novel drug class for the treatment of multiple sclerosis.

Novel Clotrimazole Analogs As Blockers Of Intermediate Conductance Kca Channels

Researchers at the University of California, Davis, have developed a method for preparing therapeutically effective amounts of triarylmethane compounds for immunosuppressive treatment of autoimmune disorders, graft rejection, and graft or host disease.

Identification And Development Of Dual nSMase2-AChE Inhibitors For Neurodegenerative Disorders

UCLA researchers in the Department of Neurology, and the Department of Chemistry & Biochemistry have developed small molecule inhibitors of both the neutral sphingomyelinase 2 (nSMase2) and acetylcholinesterase (AChE) as novel therapeutics for neurodegenerative disorders caused by protein aggregation.

New Molecular Tweezers Against Neurological Disorders And Viral Infections

UCLA researchers in the Department of Neurology with an international team of scientists have developed several new molecular tweezer derivatives with novel synthesis methods that significantly improved the therapeutic efficacy and pharmacokinetic characteristics of the drug candidates.

Drug Combinations For Treatment Of Tinnitus, Vertigo, and Headache

UC Irvine researchers propose various combinations of medications for treatment of tinnitus and vertigo.

A High Potency CYP3A4 Inhibitor for Pharmacoenhancement of Drugs

      CYP3A4 is the most clinically relevant drug metabolizing enzyme in the body, as it is responsible for the oxidation and breakdown of ~60% of current drugs on the market.  Researchers at UCI have developed novel CYP3A4 inhibitors, that are highly potent and more specific, exhibit fewer side effects, and are both cheaper, and easier to-synthesize than current commercially available CYP3A4 inhibitors. 

Novel Synthesis of Streptogramin A Antibiotics

A modular, scalable, chemical synthesis platform that produces new Streptogramin A class antibiotic candidates.

A Novel Mixture for Intravenous Sedation

UCLA researchers from the Department of Anesthesiology and Perioperative Medicine have developed a novel anesthetic mixture which combines anxielytic, narcotic, and sedation effects in a safe, effective solution.

Novel Non-Peptidomimetic Prenyltransferase Inhibitors

UCLA Researchers in the Department of Chemistry & Biochemistry and School of Medicine have synthesized a series of small molecule therapeutics against GGTase-I and GGTase-II, both of which are critical oncology drug targets.

Antibody-Interferon Fusion Proteins For Enhancing Adoptive T Cell Therapies For The Treatment Of Cancer

UCLA researchers in the Departments of Medicine and Microbiology, Immunology and Molecular Genetics have developed a novel combination therapy for enhanced efficacy of adoptive T cell therapies.

BMP Binding Proteins and Prosthetic Surfaces

UCLA researchers have developed a method to attach and enhance the activity of bone growth factors to prostheses through BMP binding proteins to increase the integration of prostheses and bone.

BBP as a Complexed Carrier for Bone Growth Factors

UCLA researchers have identified a BMP binding peptide that binds to bone growth factors to increase their residence time at the site of implantation for treatment of bone defects.

  • Go to Page: